The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment | Zendy

Hanjiao Qin | Zendy; Linlin Liu | Zendy; Shu Sun | Zendy; Dan Zhang | Zendy; Jiyao Sheng | Zendy; Bingjin Li | Zendy; Wei Yang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment

Author(s) -

Hanjiao Qin,

Linlin Liu,

Shu Sun,

Dan Zhang,

Jiyao Sheng,

Bingjin Li,

Wei Yang

Publication year - 2018

Publication title -

peerj

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.927

H-Index - 70

ISSN - 2167-8359

DOI - 10.7717/peerj.5092

Subject(s) - tumor microenvironment , pi3k/akt/mtor pathway , cancer research , breast cancer , reprogramming , angiogenesis , cancer , medicine , cytotoxic t cell , cancer cell , immune system , immunology , biology , cell , signal transduction , tumor cells , microbiology and biotechnology , in vitro , biochemistry , genetics

The phosphoinositide 3-kinase (PI3K) pathway shows frequent aberrant alterations and pathological activation in breast cancer cells. While PI3K inhibitors have not achieved expectant therapeutic efficacy in clinical trials, and several studies provide promising combination strategies to substantially maximize therapeutic outcomes. Besides its direct impact on regulating cancer cells survival, PI3K inhibitors are also demonstrated to have an immunomodulatory impact based on the tumor microenvironment. Inhibition of the leukocyte-enriched PI3K isoforms may break immune tolerance and restore cytotoxic T cell activity by reprogramming the tumor microenvironment. In addition, PI3K inhibitors have pleiotropic effects on tumor angiogenesis and even induce tumor vascular normalization. In this review, we discuss the mechanism of PI3K inhibitor suppression of breast cancer cells and modulation of the tumor microenvironment in order to provide further thoughts for breast cancer treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research